Q4 2025 · 13F-HR
AIHC Capital Management Ltdholdings as filed
Filed 2026-02-05 · accession 0001172661-26-000478
$106.7M
Reported value
6
Positions
2025-12-31
Period end
The Brief · AIHC Capital Management Ltd · Q4 2025
AI · grounded in 13F
AIHC Capital Management Ltd established a new position in Revolution Medicines Inc RVMD valued at $71.7M. The fund also initiated stakes in Protagonist Therapeutics Inc PTGX for $16.6M and Arrivent Biopharma Inc AVBP for $13M. These moves contributed to a total AUM of $106.7M across six new positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $71.7M | 67.2% | 900,392 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $16.6M | 15.5% | 189,823 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $13.0M | 12.2% | 644,788 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $3.6M | 3.33% | 100,000 | Common | SOLE |
| 44975P103 | NBP | NOVABRIDGE BIOSCIENCES | $1.6M | 1.54% | 413,979 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $242,423 | 0.23% | 30,265 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.